World Pharma News Digest

RotaTeq® Proves to Maintain High Clinical Efficacy Two Years Post-
Vaccination in Europe
In a new analysis data in the European subgroup of the large clinical
study REST (Rotavirus Efficacy and Safety Trial), the five-type
rotavirus vaccine RotaTeq® demonstrated 100% clinical efficacy against
severe rotavirus disease for the first rotavirus season after
vaccination. The efficacy remained high through two rotavirus seasons
of follow up, preventing 98% of severe rotavirus cases. This new sub-
analysis was presented last week at the 25th International Congress of
Paediatrics in Athens.
Read more...
http://www.worldpharmanews.com/content/view/75/1/

The European Leadership Summit on Chronic Care, Amsterdam, The
Netherlands
3-4 December, 2007, Amsterdam, The Netherlands
Organised under the high patronage of the European Commission, the
event will convene senior executives from key organisations advancing
chronic care in Europe including providers, payers, suppliers,
customers, policy-makers and health officials.
Read more...
http://www.worldpharmanews.com/content/view/74/1/

Pfizer Launches Five Year, Three Country Initiative for Malaria
Treatment and Education
To help address critical gaps in malaria treatment and education,
Pfizer today announced the launch of Mobilize Against Malaria. This
three-country initiative comprising Kenya, Ghana and Senegal will be
implemented over the course of five years (2007-2011). Pfizer has
selected key international and local health experts to develop and
implement public health interventions that engage and educate
treatment providers and patients in high-risk areas for the effective
treatment and management of malaria.
Read more...
http://www.worldpharmanews.com/content/view/72/1/

Study Shows IRESSA™ (Gefitinib) Is As Effective As Docetaxel In Pre-
Treated Advanced NSCLC
Data presented at the World Conference on Lung Cancer in Korea by
Professor Jean-Yves Douillard, Centre Rene Gauducheau, France,
Principal Investigator of the INTEREST study, show that patients with
non-small cell lung cancer (NSCLC) treated with the oral anti-cancer
drug IRESSA (gefitinib) had equivalent (non-inferior) survival to
those treated with intravenous docetaxel. In addition, IRESSA
demonstrated a more favourable tolerability profile and superior
quality of life for patients versus docetaxel.
Read more...
http://www.worldpharmanews.com/content/view/73/1/

Significant 30 Percent Increase in Relative Risk of Cardiovascular
Events or Death
An observational study of a large United Kingdom primary care database
showed that switching patients from Pfizer's Lipitor® (atorvastatin
calcium) Tablets to simvastatin was associated with a 30 percent
increase in the relative risk of major cardiovascular events,
including heart attacks, strokes and certain types of heart surgeries,
or death compared to patients who remained on Lipitor therapy.
Read more...
http://www.worldpharmanews.com/content/view/71/1/

Novo Nordisk Appoints New Leaders of European and North American
Regions
Novo Nordisk announced that with effect from 1 January 2008 the
company has appointed Martin Soeters to take up the position as senior
vice president of Region Europe. Martin Soeters is currently senior
vice president of Novo Nordisk North America and president of Novo
Nordisk Inc., the company's US affiliate. Martin Soeters will be
replaced by Jerzy Gruhn who will take up the position as senior vice
president of Novo Nordisk North America from the same date. Jerzy
Gruhn is currently vice president of the Europe East region within
Region Europe.
Read more...
http://www.worldpharmanews.com/content/view/70/1/

AstraZeneca Enhances Clinical Research Capabilities in China
AstraZeneca today announced a strategic partnership with Peking
University 3rd Hospital to open its first Clinical Pharmacology Unit
(CPU) in China. The unit aims to enhance local clinical research
capabilities and speed up access to new medicines to benefit Chinese
patients.
Read more...
http://www.worldpharmanews.com/content/view/69/1/

With best regards,
Ruslan David, MD
eHealthNews.EU Portal & World Pharma News
Administrator/Editor
Tel.: +49 (0) 681 7097881
http://www.ehealthnews.eu
http://www.worldpharmanews.com

.

Relevant Pages

  • UK patients more prone to MRSA
    ... UK patients 'more prone to MRSA' ... UK hospital patients are among the most likely in Europe to catch ... Mr Wilkinson said one problem was a tendency in many hospitals across ...
    (uk.business.agriculture)
  • Bioms Medical Commences U.K. Patient Enrollment in Multiple Sclerosis Trial
    ... Bioms Medical Commences U.K. Patient Enrollment in Multiple ... "The successful expansion of our pivotal trial into Europe is ... portion of MS patients globally with approximately 85,000 MS ... sclerosis and is currently in a pivotal Phase II/III clinical ...
    (alt.support.mult-sclerosis)